Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01967823
Title T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

meningioma

Advanced Solid Tumor

melanoma

Therapies

Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine

Age Groups: adult | senior | child
Covered Countries USA


No variant requirements are available.